- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Iadademstat, Atezolizumab, SBRT
- Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 17,842
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oral Mucositis
- Interventions
- Neem Mouthrinse, Placebo Mouthrinse
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Healthy
- Interventions
- Placebo, 611
- Drug
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HCV Infection
- Interventions
- ABT-072, ketoconazole, Placebo
- Drug · Other
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Waukegan, Illinois
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- doxorubicin hydrochloride, motexafin gadolinium
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Madison, Wisconsin
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
- Interventions
- Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Interventions
- MB-102, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Mustang Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Duarte, California • Boston, Massachusetts • Durham, North Carolina + 1 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg, GSK233705 100mcg, GSK233705 200mcg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 25
- States / cities
- Jasper, Alabama • Glendale, Arizona • Fountain Valley, California + 21 more
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor
- Interventions
- APR-246 (eprenetapopt) + Pembrolizumab
- Drug
- Lead sponsor
- Aprea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
- Conditions
- ADHD
- Interventions
- OROS-Methylphenidate (MPH)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Seattle, Washington
- Conditions
- Growth Hormone Deficiency
- Interventions
- TV-1106, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 25
- States / cities
- Artesia, California • Fountain Valley, California • Miami, Florida + 15 more
- Conditions
- Cellulite
- Interventions
- Collagenase Clostridium Histolyticum-Aaes, Lysteda 650 MG Oral Tablet
- Drug
- Lead sponsor
- Luxurgery
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Subjects
- Interventions
- PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Glendale, California
- Conditions
- Glomerulosclerosis, Focal Segmental
- Interventions
- Losmapimod
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- TBI 302
- Biological
- Lead sponsor
- Evolve Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Weight Management
- Interventions
- ASC30, Placebo
- Drug · Other
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- HIV-1-infection
- Interventions
- Elsulfavirine
- Drug
- Lead sponsor
- Viriom
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Headache Disorders
- Interventions
- massage, Spinal manipulation
- Procedure
- Lead sponsor
- University of Western States
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Interleukin-2
- Drug
- Lead sponsor
- Ralph Hauke
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Fanconi Anemia, Severe Aplastic Anemia
- Interventions
- CAMPATH-1H, Anti-CD45, Fludarabine, Stem cell infusion
- Biological · Drug · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Venous Thromboembolism, Pharmacokinetics, Healthy
- Interventions
- Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Constipation
- Interventions
- Senna+ docusate, placebo
- Drug
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Hematologic Malignancies
- Interventions
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
- Device · Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK1614235, Sitagliptin, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio